XLY Fundamental Analysis - AUXLY CANNABIS GROUP INC

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to XLY. XLY was compared to 34 industry peers in the Pharmaceuticals industry. While XLY is still in line with the averages on profitability rating, there are concerns on its financial health. XLY is growing strongly while it is still valued neutral. This is a good combination!

Quickly go to:

1. Profitability

1.1 Basic Checks

XLY had positive earnings in the past year.

In the past year XLY had a positive cash flow from operations.

XLY had negative earnings in each of the past 5 years.

In multiple years XLY reported negative operating cash flow during the last 5 years.

1.2 Ratios

XLY has a better Return On Assets (8.22%) than 97.06% of its industry peers.

XLY's Return On Equity of 16.98% is amongst the best of the industry. XLY outperforms 94.12% of its industry peers.

		Industry Rank	Sector Rank
ROA	8.22%
ROE	16.98%
ROIC	N/A

ROA(3y)-20.84%

ROA(5y)-18.51%

ROE(3y)-81.82%

ROE(5y)-60.99%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

XLY's Profit Margin of 16.78% is amongst the best of the industry. XLY outperforms 94.12% of its industry peers.

XLY has a Gross Margin of 20.80%. This is in the lower half of the industry: XLY underperforms 73.53% of its industry peers.

In the last couple of years the Gross Margin of XLY has grown nicely.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	16.78%
GM	20.8%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y3.43%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

XLY does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, XLY has more shares outstanding

The number of shares outstanding for XLY has been increased compared to 5 years ago.

Compared to 1 year ago, XLY has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -1.36, we must say that XLY is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -1.36, XLY is not doing good in the industry: 67.65% of the companies in the same industry are doing better.

The Debt to FCF ratio of XLY is 3.54, which is a good value as it means it would take XLY, 3.54 years of fcf income to pay off all of its debts.

With an excellent Debt to FCF ratio value of 3.54, XLY belongs to the best of the industry, outperforming 85.29% of the companies in the same industry.

XLY has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.

Looking at the Debt to Equity ratio, with a value of 0.11, XLY is in the better half of the industry, outperforming 67.65% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.11
Debt/FCF	3.54
Altman-Z	-1.36

ROIC/WACCN/A

WACC8.67%

2.3 Liquidity

XLY has a Current Ratio of 0.68. This is a bad value and indicates that XLY is not financially healthy enough and could expect problems in meeting its short term obligations.

XLY's Current ratio of 0.68 is on the low side compared to the rest of the industry. XLY is outperformed by 91.18% of its industry peers.

A Quick Ratio of 0.34 indicates that XLY may have some problems paying its short term obligations.

With a Quick ratio value of 0.34, XLY is not doing good in the industry: 88.24% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.68
Quick Ratio	0.34

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

XLY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 151.35%, which is quite impressive.

Looking at the last year, XLY shows a very strong growth in Revenue. The Revenue has grown by 21.02%.

XLY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 71.07% yearly.

EPS 1Y (TTM)151.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

Revenue 1Y (TTM)21.02%

Revenue growth 3Y13.43%

Revenue growth 5Y71.07%

Sales Q2Q%32.17%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

The Revenue is expected to grow by 22.57% on average over the next years. This is a very strong growth

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year18.98%

Revenue Next 2Y26.62%

Revenue Next 3Y26.12%

Revenue Next 5Y22.57%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

XLY is valuated cheaply with a Price/Earnings ratio of 5.17.

94.12% of the companies in the same industry are more expensive than XLY, based on the Price/Earnings ratio.

When comparing the Price/Earnings ratio of XLY to the average of the S&P500 Index (27.17), we can say XLY is valued rather cheaply.

		Industry Rank	Sector Rank
PE	5.17
Fwd PE	N/A

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, XLY is valued cheaply inside the industry as 82.35% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	11.29
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

XLY does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AUXLY CANNABIS GROUP INC

TSX:XLY (8/28/2025, 7:00:00 PM)

0.155

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-14 2025-08-14/bmo

Earnings (Next)11-06 2025-11-06

Inst Owners0.01%

Inst Owner ChangeN/A

Ins Owners4.63%

Ins Owner ChangeN/A

Market Cap208.34M

Analysts45.71

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	5.17
Fwd PE	N/A
P/S	1.61
P/FCF	11.29
P/OCF	9.93
P/B	1.62
P/tB	2.11
EV/EBITDA	N/A

EPS(TTM)0.03

EY19.35%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.01

FCFY8.86%

OCF(TTM)0.02

OCFY10.07%

SpS0.1

BVpS0.1

TBVpS0.07

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	8.22%
ROE	16.98%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	16.78%
GM	20.8%
FCFM	14.22%

ROA(3y)-20.84%

ROA(5y)-18.51%

ROE(3y)-81.82%

ROE(5y)-60.99%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y3.43%

GM growth 5YN/A

F-Score6

Asset Turnover0.49

Health

		Industry Rank	Sector Rank
Debt/Equity	0.11
Debt/FCF	3.54
Debt/EBITDA	N/A
Cap/Depr	24.46%
Cap/Sales	1.95%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	84.76%
Current Ratio	0.68
Quick Ratio	0.34
Altman-Z	-1.36

F-Score6

WACC8.67%

ROIC/WACCN/A

Cap/Depr(3y)27.93%

Cap/Depr(5y)61.49%

Cap/Sales(3y)4.52%

Cap/Sales(5y)11.68%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)151.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)21.02%

Revenue growth 3Y13.43%

Revenue growth 5Y71.07%

Sales Q2Q%32.17%

Revenue Next Year18.98%

Revenue Next 2Y26.62%

Revenue Next 3Y26.12%

Revenue Next 5Y22.57%

EBIT growth 1Y51.04%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year399.98%

EBIT Next 3Y106.86%

EBIT Next 5Y66%

FCF growth 1Y1625.29%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y171.42%

OCF growth 3YN/A

OCF growth 5YN/A

AUXLY CANNABIS GROUP INC (XLY.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens